The aim of this study was to investigate changes in the concentration of UPIIIa and UPII in the urine and plasma of patients with selected benign diseases of the urinary tract, such as BPH, US, UTI and urolithiasis, in comparison to healthy people with excluded urological diseases, who constituted the control groups. This evidence concerns the gene UPK2 and urolithiasis.